

## Data Sheet (13-Year Summary of Consolidated Financial Results of ASKA Pharmaceutical Holdings)

	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012
<b>Consolidated Financial Results (Millions of yen)</b>													
Net sales	<b>64,139</b>	62,843	60,461	56,607	55,181	52,542	46,706	48,944	48,527	43,215	42,907	39,501	40,963
Cost of sales	<b>32,803</b>	32,178	31,876	30,255	29,798	28,525	27,814	30,059	29,614	26,072	25,717	22,431	23,047
Selling, general and administrative expenses	<b>26,003</b>	24,164	23,476	21,556	21,773	22,509	17,107	16,060	17,119	15,861 <sup>*5</sup>	15,767	16,353	16,847
Operating profit	<b>5,331</b>	6,500	5,108	4,795	3,609	1,507	1,782	2,824	1,793	1,283 <sup>*6</sup>	1,425	716	1,061
Ordinary profit	<b>5,107</b>	6,522	5,232	4,880	3,092	1,715	1,980	3,073	2,002	1,522	1,722	1,031	1,336
Profit attributable to owners of parent	<b>5,101</b>	7,545	4,238	4,290	2,713	649	1,744	2,388	2,944	701	1,193	495	1,114
R&D expenses	<b>7,031</b>	4,728	4,227	3,598	4,709	4,913	4,493	4,055	4,970	4,174	4,025	4,144	4,269
Capital expenditures (Property, plant and equipment and software (transfer basis))	<b>2,700</b>	1,540	1,256	657	765	2,040	2,994	1,443	772	2,279	2,285	2,047	937
Depreciation	<b>2,247</b>	2,662	3,127	2,885	3,305	3,669	2,491	2,324	2,447	1,969	1,709	2,355	2,353
<b>Consolidated Financial Position (Millions of yen)</b>													
Total assets	<b>100,534</b>	90,745	87,138	83,297	82,582	80,239	82,194	66,235	66,126	57,478	58,933	51,269	51,770
Net assets	<b>69,195</b>	61,930	54,533	48,892	44,510	41,573	43,456	42,559	39,511	35,961	36,577	33,941	33,350
Interest-bearing debt	<b>10,903</b>	9,485	12,623	14,046	16,395	16,419	16,468	2,950	3,700	5,708	1,366	1,557	1,782
<b>Consolidated Cash Flows (Millions of yen)</b>													
Cash flows from operating activities	<b>2,485</b>	1,486	3,351	2,842	6,541	-492	2,504	76	12,063	-1,349	5,710	2,616	3,869
Cash flows from investing activities	<b>-6,124</b>	1,706	-1,126	6,743	-2,866	-2,927	-14,780	-3,348	-378	-6,776	-1,897	-2,301	-1,484
Cash flows from financing activities	<b>-2,956</b>	-3,943	-1,820	-2,996	-455	-392	13,036	-1,142	-2,384	4,013	-557	-574	124
Cash and cash equivalents at end of period	<b>10,603</b>	16,738	17,505	17,103	10,514	7,294	11,107	10,346	14,761	5,462	9,574	6,318	6,578
<b>Per-share Data (Yen)</b>													
Earnings per share	<b>179.95</b>	266.51	150.08	151.22	95.72	22.96	61.81	84.80	105.39	25.15	42.89	17.85	40.27
Net assets per share	<b>2,302.61</b>	2,186.10	1,928.14	1,734.80	1,568.89	1,467.58	1,538.75	1,509.70	1,413.51	1,287.76	1,313.20	1,219.32	1,202.59
Dividends per share	<b>55</b>	40	16	15	14	17 <sup>*4</sup>	14	14	14	14	14	14	14
<b>Financial Ratios (%)</b>													
Cost of sales ratio	<b>51.1</b>	51.2	52.7	53.4	54.0	54.3	59.6	61.4	61.0	60.3	59.9	56.8	56.3
Selling, general and administrative expenses ratio	<b>40.5</b>	38.5	38.8	38.1	39.5	42.8	36.6	32.8	35.3	36.7	36.7	41.4	41.1
Operating profit margin	<b>8.3</b>	10.3	8.4	8.5	6.5	2.9	3.8	5.8	3.7	2.7	3.3	1.8	2.6
Equity ratio	<b>65.0</b>	68.2	62.6	58.7	53.9	51.8	52.9	64.3	59.8	62.6	62.1	66.1	64.4
Profit attributable to owners of parent / Equity (ROE)	<b>5.3</b>	7.3	6.1	5.9	3.8	2.1	2.7	4.6	3.2	2.6	3.1	2.0	2.6
Ordinary profit / Total assets (ROA)	<b>8.0</b>	13.0	8.2	8.8	6.3	1.5	4.1	5.8	7.8	1.9	3.4	1.5	3.4
Dividend payout ratio	<b>30.6</b>	15.0	10.7	5.3 <sup>*3</sup>	14.6	74.0	22.7	16.5	13.3	55.7	32.6	78.4	34.8
<b>Non-financial Information</b>													
Number of employees	<b>1,632 <sup>*1</sup></b>	762	747	777	800	807	842	856	862	872	862	886	897
Number of issued shares (Thousands)	<b>28,763 <sup>*2</sup></b>	30,563	30,563	30,563	30,563	30,563	30,563	30,563	30,563	30,563	30,563	30,563	30,563

Notes:

Figures up to FY2020 are the figures announced by ASKA Pharmaceutical Co., Ltd.

\*1. The addition of overseas operations has increased the number of employees by 857.

\*2. 1,800 thousand shares decreased from the previous period due to the cancellation of treasury stock based on the resolution of the Board of Directors.

\*3. Interim dividends are dividends from other capital surplus and are excluded from the dividend payout ratio.

\*4. 100th anniversary commemorative dividend of ¥3 per share.

\*5. Due to a change in presentation, Selling, general and administrative expenses for FY2015 were adjusted from ¥15,978 million to ¥15,861 million.

\*6. Due to a change in presentation, Operating profit for FY2015 was adjusted from ¥1,166 million to ¥1,283 million.